Form 4: ADMA Biologics COO Kaitlin Kestenberg-Messina Reports Stock Transactions

Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reports acquisition and disposal of ADMA common stock and stock options.

Summary

• On March 31, 2024, shares were withheld by ADMA Biologics to cover tax obligations related to vesting restricted stock units (RSUs) at a price of $6.6, resulting in a disposal of 2,085 shares.
• As of March 31, 2024, Kestenberg-Messina directly owns 112,190 shares of ADMA Biologics common stock acquired through RSU vesting.
• On April 1, 2024, Kestenberg-Messina was granted 192,320 RSUs, which will vest in four equal annual installments.
• Following these transactions, Kestenberg-Messina directly owns 304,510 shares, including vested shares and unvested RSUs.
• On April 1, 2024, Kestenberg-Messina was granted a stock option to purchase 300,328 shares of common stock at an exercise price of $6.54, expiring on April 1, 2034.
• The stock option vests over four years, with 25% vesting on the first anniversary and the remaining 75% vesting monthly over the subsequent three years.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The grant of RSUs and stock options to a key executive like the COO and SVP of Compliance suggests the company is incentivizing long-term performance and alignment with shareholder interests.
• The vesting schedule of the RSUs and stock options encourages continued service and commitment from the executive.

Future Outlook

The RSUs will vest in four equal installments on each annual anniversary of the grant date, contingent upon continued service. The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting monthly over the subsequent three years.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and provide transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions reported in the Form 4 filing may be of interest to shareholders as they provide insight into the executive's holdings and incentives.
• The vesting of RSUs and stock options can motivate the executive to work towards the long-term success of the company, benefiting shareholders.

Key Dates